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Objective: The purpose of this study was to evaluate the effectiveness of a sustained-release sheet with vancomycin (VCM)
to prevent prosthetic graft infection.
Methods:VCMwas incorporated into a poly-L-lactide-co-caprolactone (PLCA) sheet (VCM-PLCA). The release profile of
VCM from the VCM-PLCA sheet and the tissue concentration of VCM released in vivo were examined. To assess the
antibacterial effect of the VCM-PLCA sheet, a sterile Dacron sheet was implanted into 96 male mice (C57BL/6), who
were randomly divided into four groups of 24 each and treated as follows: no treatment (group A, control group), a local
bolus injection of an aqueous solution of VCM (group B), a plain PLCA sheet (group C), and a VCM-PLCA sheet (group
D). After the treatment, methicillin-resistant Staphylococcus aureus (MRSA) (1  106 colony forming units) was
inoculated onto the Dacron graft surface. The Dacron grafts were retrieved on days 3, 7, 10, and 14 after the
implantation, and the number of MRSA in the Dacron grafts was counted.
Results: VCM was slowly released from the VCM-PLCA sheet over 2 weeks in vivo, and the mean in vivo concentrations
of VCM in the tissue around a VCM-PLCA sheet were 7.95, 26.39, 13.87, 12.51, 8.36, and 10.33g/mL (theminimum
inhibitory concentration of VCM against MRSA is 2.0 g/ml), at 1, 2, 5, 7, 10, and 14 days after the implantation,
respectively. MRSA colonization on the cultivated agar plates was detected in all samples from groups A, B, and C at any
postoperative time points. In contrast, some samples were negative for bacterial cultures in group D (2, 3, 1, and 2
samples out of 6 samples each on days 3, 7, 10, and 14 after the implantation, respectively). At all time points, the number
of MRSA bacteria in the implanted Dacron graft in group D was by far the lowest (P < .01 at each time point).
Conclusions: The sustained-release sheet with VCM appears to be effective for the reduction of subcutaneous prosthetic
graft infection. (J Vasc Surg 2006;44:377-82.)
Clinical Relevance: Prosthetic graft infection is one of the most serious complications after vascular surgery. Because its
prevention is extremely important, novel strategies are needed to suppress the bacterial growth around the prosthetic
graft. The sustained-release sheet with vancomycin may a promising tool in the prevention of prosthetic graft infection.Prosthetic graft infection after vascular surgery is well
known as an extremely serious complication. Although the
incidence of such infection varies from 0.5% to 5%, the
mortality rates are generally very high,1-3 and infection
prevention is of vital importance. Infection with pathogenic
bacteria such as methicillin-resistant Staphylococcus aureus
(MRSA) is likely to develop in critically ill patients,4,5 and
systemic administration of antibiotics often is not effective.
The main pathogenesis of prosthetic graft infection is bac-
terial contamination of the prosthetic graft and surround-
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doi:10.1016/j.jvs.2006.03.043ing tissue at the time of surgery.6 Novel techniques for
delivering antibiotics locally to suppress bacterial growth
around the prosthetic graft are therefore essential.
After the surgical treatment, antibiotics are usually
administrated systematically to prevent all forms of in-
fection. This is often insufficient to prevent prosthetic
graft infection because the tissue concentration of anti-
biotics around the prosthetic graft may be quite low.6 To
maintain effective tissue concentration of antibiotics
around the prosthetic graft for a sufficient length of time
is thus highly desirable.7 Systemic administration of
high-dose antibiotics may induce systemic side effects,
however. We therefore hypothesized that local adminis-
tration of a sustained-release form of antibiotics might be
less invasive and more effective for the prevention of
prosthetic graft infection.
We have recently developed a sustained-release system
of antibiotics using poly-L-lactide-co-caprolactone
(PLCA). In this study, we tested our hypothesis that a
sustained-release sheet with vancomycin (VCM) may be
effective to prevent prosthetic graft infection due to MRSA
in a murine model.
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Preparation of PLCA sheet incorporating vancomycin.
Biodegradable polymers are frequently used as carriers of
sustained-release drugs, and PLCA was selected for this
purpose in the present study. The number of available
degradable polymers is limited, however, and only a few
polymers have been approved by the Food and Drug Ad-
ministration, such as aliphatic polyesters including polylac-
tic acid (PLA), polyglycolic acid (PGA), and polydioxanone
(PDS), all of which are already used routinely for sustained
drug delivery.8-11 The PLCA we used in the present study
(50:50 polymer with Mw 282,352) was kindly supplied by
BMG Co, Ltd. (Kyoto, Japan).
PLCA sponges containing VCM were prepared. An
aqueous phase consisting of VCM (13.32 mg) in 0.3 mL of
double-distilled water was prepared. The aqueous phase
was then added into 2.7 mL of 1,4-dioxane containing
69.0 mg of PLCA and agitated with a TM-252 vortex
mixer (Asahi Techno Glass Co, Chiba, Japan) for 60 sec-
onds, a Polytron PT3100 homogenizer (Ishii Laboratory
Works Co, Ltd, Osaka, Japan) for 60 seconds, and an
US150 ultrasonic generator (Nissei Co, Ltd, Tokyo, Japan)
for 60 seconds. The solution was placed into a glass dish
(5.6 cm2) and lyophilized to make the sheet. The thus
prepared PLCA sheet incorporating VCM (VCM-PLCA
sheet) was a 1-mm thick, 10-mm 10-mm square. All the
procedures were conducted under sterile conditions.
Experiment 1: Release profile of VCM from PLCA
sheet and tissue concentration of VCM around the
sheet. The release profile of VCM from the VCM-PLCA
sheet and the concentration of VCM in the tissue around
the sheet were examined in vivo. Seventy-two male mice
(C57BL/6) weighing approximately 20 g were anesthe-
tized intraperitoneally with sodium pentobarbital (100
g/g). A 10-mm horizontal incision in the center of the
back, with the mouse in the prone position, was made to
expose the subcutaneous tissue and to make a subcutane-
ous pocket. In the present study, the purchased
Hemashield (Boston Scientific, Natick, Mass) woven Da-
cron grafts (which we believe are in wide clinical use) were
cut into 10-mm 10-mm squares and applied as a Dacron
sheet after sterilization.
Themice were randomized into two groups of 36 each:
a VCM-PLCA group with implantation into the pocket of
a sterile 10-mm 10-mmDacron sheet and a VCM-PLCA
sheet incorporating 2.38 mg of VCM, and the VCM-
solution group with implantation of a sterile Dacron sheet
and a local bolus injection of an aqueous solution of 2.38
mg of VCM (the same amount as that contained in a
VCM-PLCA sheet) dissolved in 0.2 mL of physiologic
saline. The sheets were immobilized with 7-0 polypro-
pylene sutures, and the skin was carefully sutured with 7-0
nylon monofilaments.
On days 1, 2, 5, 7, 10, and 14 after the implantation, six
mice per group were euthanized with an intraperitoneal
administration of a lethal dose of sodium pentobarbital,
and the remaining VCM-PLCA sheet and the subcutane-ous tissue (20-mm  20-mm square and 2-mm thick)
immediately above and below the Dacron sheet were har-
vested. VCM remaining in the harvested VCM-PLCA
sheet was extracted into an organic solvent (dichlorometh-
ane), and the precipitant was dissolved into physiologic
saline. The amount of released VCM was measured at 280
nm using a spectrophotometer.
After the tissue around the Dacron sheet had been
weighed, it was homogenized with 10 mL of phosphate-
buffered saline solution (PBS) at 15,000 rpm for 15 min-
utes in a blender. The emulsion was then centrifuged at
5000 rpm for 15 minutes in a centrifugal machine, and the
amount of VCM in the supernatant fluid was measured as
previously described. The tissue concentration was defined
as the ratio of the amount of VCM to the volume of PBS for
the same weight of tissue (g/mL).
All animals were cared for in compliance with theGuide
for the Care and Use of Laboratory Animals, Institute of
Laboratory Animal Resources, Commission on Life Sci-
ences, National Research Council. All of the assessments
were done by investigators who were blinded to the group-
ing of mice.
Experiment 2: Prevention of graft infection inocu-
lated by MRSA. To examine the level of bacterial coloni-
zation on transplanted materials, the number of MRSA
bacteria in the Dacron sheet was counted after MRSA
inoculation. Ninety-six male mice (C57BL/6) were anes-
thetized, the subcutaneous tissue was exposed, and a sub-
cutaneous pocket made in the same way as in the first
experiment. Themice were randomized into four groups of
24 each according to the type of implantation in the sub-
cutaneous pocket: group A (control group) with implanta-
tion of a sterile Dacron sheet (10-mm  10-mm, 1-mm
thick) only, group B with implantation of a Dacron sheet
and a local bolus injection of an aqueous solution of VCM
(2.38 mg dissolved in 0.2 mL of physiologic saline), group
C with implantation of a Dacron sheet and a plain PLCA
sheet, and group D with implantation of a Dacron sheet
and a VCM-PLCA sheet (2.38 mg). The graft (with the
VCM-PLCA sheet) was immobilized with 7-0 polypro-
pylene sutures, and the skin was carefully sutured with 7-0
nylon monofilaments.
MRSA inoculation. After skin closure, a sterile saline
solution (0.2mL) containing 1 106 colony forming units
(CFU) of the MRSA SR3737 strain was inoculated onto
the graft surface by means of a tuberculin syringe to create
a subcutaneous fluid-filled pocket.12 On days 3, 7, 10, and
14 after the MRSA inoculation, six mice per group were
euthanized as previously described and the Dacron graft
was pulled out from the subcutaneous tissue.
Evaluation of bacterial colonization (CFU assay).
The removed Dacron sheets were homogenized with 10
mL of PBS at 15,000 rpm for 5 minutes with an Ace
Homogenizer AM-7 blender (Nihonheiki Kaisha, Ltd, To-
kyo, Japan). The homogenates were serially diluted 10-fold
and 0.1-mL samples were plated on normal agar plates
(Eiken Chemical Co, Ltd, Tokyo, Japan). The plates were
incubated at 37°C for 18 hours. The number of colonies
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original sample was calculated.
Blood examination. Blood was sampled from each
mouse for hematologic tests (blood cell counts, differential
count of leukocytes), blood culture, and measurement of
the serum concentration of VCM on day 3, 7, 10, and 14
after the MRSA inoculation (n  6 per group per day).
Experiment 3: Evaluation of infection/inflamma-
tion around the transplanted material after MRSA
inoculation. Histologic studies were also performed to
assess the level of infection/inflammation around the trans-
planted materials after the MRSA inoculation. Thirty male
mice (C57BL/6) were anesthetized and operated on in the
same way as for animal experiment 2. They were random-
ized into five groups of six each: group A, implanted
Dacron sheet only; group B, a Dacron sheet and a local
bolus injection of an aqueous solution of VCM; group C, a
Dacron sheet and a plain PLCA sheet; group D, a Dacron
sheet and a VCM-PLCA sheet; and group E, a Dacron
sheet and a VCM-PLCA sheet (same as group D).
After the implantation, a sterile saline solution (0.2
mL) containing 1  106 CFU of the MRSA strain was
inoculated in the same manner as in animal experiment 2
onto the graft surface inmice in groups A throughD. Seven
days after the MRSA inoculation, macroscopic examina-
tions were done from the surgical site, and the mice were
then euthanized as previously described. The tissues
around the implanted Dacron sheet, including skin, subcu-
taneous tissue, and muscle fiber, were sampled and fixed
with a 10% formaldehyde solution in PBS solution. Each
sample was embedded in paraffin, cut into 3-m thick
slices, and stained with hematoxylin and eosin and Gram.
Statistical analysis. Experimental results are ex-
pressed as the mean  standard deviation. For multiple
comparisons among independent groups in which analysis
of variance indicated significant differences, the statistical
value was determined with the Bonferroni/Dunn method.
Differences between groups were determined with the
unpaired Student’s t test. StatView software (StatView
Corp, Cary, NC)was used for all statistical analyses. P .05
was considered significant.
RESULTS
Experiment 1
Release profile of VCM from PLCA sheet. Fig 1
shows the curve for VCM release from the VCM-PLCA
sheet. The sheet progressively degraded and decreased in
size after the implantation and had become considerably
smaller by day 14 after the implantation. The drug release
ratios were 16.1%  5.9% on day 1, 38.9%  5.4 % on day
2, 52.4%  63 % on day 5, 68.6%  6.1% on day 7, 78.2%
 6.4% on day 10, and 89.2%  6.4% on day 14. These
results indicate that the VCM-PLCA sheet continued to
release the drug (VCM) for approximately 2 weeks.
Tissue concentration of VCM around the sheet. Fig
2 shows the time course of VCM concentration in the tissue
around the Dacron sheet. The tissue concentrations for theVCM-PLCA group were 7.95  3.01 g/mL on day 1,
26.39  8.71 g/mL on day 2, 13.87  4.70 g/mL on
day 5, 12.51 3.50g/mLon day 7, 8.36 3.06g/mL
on day 10, and 10.33  4.24 g/mL on day 14. In
contrast, although the tissue concentrations of VCM for
the VCM-solution group was 10.20 6.75g/mL on day
1, that on day 2 decreased to 1.46  1.34 g/mL, which
was below theminimum inhibitory concentration (MIC) of
VCM againstMRSA (2.0 g/mL). In addition, concentra-
tions on days 5, 7, 10, and 14 were all below the detectable
limit (0.2 g/mL). These results indicate that the VCM-
solution was dissipated very quickly but that VCM released
from the VCM-PLCA sheet was maintained for 2 weeks in
Fig 1. Profile of vancomycin (VCM) release from a VCM-poly-
L-lactide-co-caprolactone (PLCA) sheet. The x-axis shows the
time course and the y-axis shows the percentage of VCM remaining
in the harvested sheet.
Fig 2. Tissue concentration of vancomycin (VCM) around the
Dacron sheet. The x-axis shows the time course and the y-axis
shows the concentration of VCM (g/mL). VCM-poly-L-lactide-
co-caprolactone (PLCA) group (closed circle, solid line): implanta-
tion of a sterile Dacron sheet and a VCM-PLCA sheet; VCM-
solution group (open circle, dotted line): implantation of a sterile
Dacron sheet and a local bolus injection of an aqueous solution of
VCM.the tissue surrounding the sheet.
tion o
a VC
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Number of MRSA in the implanted Dacron graft
(CFU assay). No bacteria other than MRSA were de-
tected on the cultivated agar plates in this study. MRSA
colonization was found on the plates in all samples of
groups A, B, and C at any of the postoperative time points.
In contrast, some samples were negative for bacterial cul-
tures in group D for which the VCM-PLCA sheet was used
(2 of 6 samples on day 3, 3 of 6 samples on day 7, 1 of 6
samples on day 10, and 2 of 6 samples on day 14 day).
The upper row of Table I presents the infection rate.
The infection rate was defined as the ratio of the number of
bacterial culture positive samples to that of all samples. The
lower row of Table 1 also shows the number of MRSA
bacteria in the removed Dacron graft.
There were no statistically significant differences
among groups A, B, and C in the numbers of MRSA
bacteria on days 3, 7, 10, and 14. The MRSA count for
group D, on the other hand, was significantly lower than
that of the other groups (P .01). These results show that
group D had best results among the four groups at all
postoperative time points. In addition, the number of
MRSA bacteria in group D did not increase with time,
probably due to the effect of the sustained-release of VCM.
Blood examination. The blood samples obtained at
the time of euthanasia of the mice in experiment 2 showed
no significant differences in hematologic parameters (blood
Table I. The number of as methicillin-resistant Staphyloco
Day Group A (n  6) Group B (n  6
3 0 (100%) 0 (100%)
(2.41  0.78)  107 (1.68  0.81)  1
7 0 (100%) 0 (100%)
(2.35  0.91)  107 (1.49  0.94)  1
10 0 (100%) 0 (100%)
(2.90  0.98)  107 (2.31  0.92)  1
14 0 (100%) 0 (100%)
(3.69  1. 62)  107 (3.63  1.02)  1
The upper rows show the number of samples without MRSA (and the infect
number of MRSA with measurable counts.) The infection rate was defined as
Group A, no treatment; Group B, a local bolus injection of an aqueous solu
*P  .01 vs Group A, B, and C.
Table II. Macroscopic findings at the surgical site on day
Group A
Skin erosion 6
Skin ulcer 3
Abscess around the Dacron graft 2
Complete wound healing 0
N  6 for all groups. Group A, no treatment; Group B, a 10cal bolus injec
VCM-PLCA sheet (MRSA inoculation for Group A through D). Group E,cell counts, differential count of leukocytes). Blood culturesamples from all groups were negative on any sampling day.
These results indicate an absence of systemic infection. The
serum VCM concentration was below the detection limit
(0.2 g/mL) in all samples.
Experiment 3
Macroscopic findings. Macroscopic findings of the
surgical site on day 7 after the surgery in animal experiment
3 are presented in Table II. Severe inflammation, including
skin ulcers and abscesses, was seen in most mice in groups
A, B, and C. However, the mice in groups D and E showed
only slight inflammation as a result of the surgical manipu-
lations. Surgical wounds completely healed in five of the six
mice in groups D and E, but none of the surgical wounds of
the mice in groups A, B, and C completely healed.
Histologic examination. Photomicrographs of the
tissues around the Dacron graft on postoperative day 7 in
experiment 3 are shown in Fig 3. In group E (treated with
a VCM-PLCA sheet without MRSA), only mild inflamma-
tion resulting from the surgical manipulations was seen. In
samples stained with hematoxylin and eosin from groups A,
B, and C, MRSA bodies and severe inflammation such as
edematous and congestive changes and permeation of in-
flammatory cells around theDacron graft were observed. In
addition,MRSA bodies were also found in the Dacron fiber
in Gram-stained samples from group A, B, and C. How-
ever, in samples of group D treated with the VCM-PLCA
ureus in the transplanted materials
Group C (n  6) Group D (n  6)
0 (100%) 2 (67%)
(2.19  0.92)  107 (1.06  0.94)  103*
[(1.60  0.57)  103]*
0 (100%) 3 (50%)
(1.94  1.16)  107 (1.15  0.92)  103*
[(1.73  0.28)  103]*
0 (100%) 1 (83%)
(2.46  0.81)  107 (1.58  1.11)  103*
[(1.90  0.89)  103]*
0 (100%) 2 (67%)
(3.20  1.61)  107 (1.45  1.15)  103*
[(2.17  0.32)  103]*
te), and the lower rows show the MRSA count in the Dacron sheet ([ ]; the
tio of the number of bacterial culture positive samples to that of all samples.
f VCM; Group C, a plain PLCA sheet; Group D, a VCM-PLCA sheet.
er surgery
p B Group C Group D Group E
6 1 1
3 0 0
2 0 0
0 5 5
f an aqueous solution of VCM; Group C, a plain PLCA sheet; Group D, a
M-PLCA sheet without MRSA inoculation.ccus a
)
07
07
07
07
ion ra
the ra7 aft
Grou
6
3
1
0
tion osheet, only slight inflammation around the Dacron sheet
-PLC
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found in the Dacron fiber.
DISCUSSION
In this study, we developed a sustained-release sheet
with VCMmade of PLCA, a biodegradable material. VCM
was slowly released over 2 weeks from the VCM-PLCA
sheet. The most noteworthy finding was that in the murine
model of subcutaneous prosthetic graft infection, the
sustained-release sheet with VCM reduced prosthetic graft
infection.
The VCM sustained-release sheet has twomajor advan-
tages. The first is the local and sustained delivery of VCM.
The maintenance of an effective tissue concentration of
antibiotics in the infected area for a sufficient period should
contribute to the prevention of prosthetic graft infection.7
Systemic administration of antibiotics is often insufficient
for the prevention of prosthetic graft infection because of
the low concentration of antibiotics in the operative
field.6,13 The topical use of the sustained-release sheet with
VCM allowed a high tissue VCM concentration to be
maintained for a certain period at the surgical site. Since
serum concentration of VCM released from the VCM
Fig 3. Micrographs of the tissue around the Dacron sh
Only slight inflammation was seen (arrow, Dacron sh
inflammation such as edematous and congestive change a
including skin dehiscence was observed (black arrow, sk
resistant Staphylococcus aureus [MRSA]) (HE stain,10
remaining VCM-PLCA sheet) (HE stain, 100). D, Ba
(Gram stain,400).E, No bacterial cells ofMRSAwere f
inoculation; group D, a Dacron sheet with a vancomyc
MRSA inoculation; group E, a Dacron sheet with a VCMsustained-release sheet at the subcutis was eventually neg-ligible, concerns about the systemic effects of VCM appear
not to be warranted.
The second advantage is the ease of use. The sustained-
release sheet with VCM is soft, easy to handle, and can
conveniently be cut to the appropriate size so that it readily
conforms to the shape of tissues and grafts. The sustained-
release sheet with VCM can be placed at any targeted area
during the surgical treatment, and the range of use is also
unrestricted.
Because PLCA had the best release profile of VCM for
our purpose,we selected it fromamong various biodegradable
polymers as the material of the sustained-release sheet of
VCM. The amount of VCM incorporated into the PLCA
sheet was determined so that the tissue concentration of
VCM around the VCM sustained-release sheet would exceed
the level of the MIC of VCM against MRSA in any samples
onday 14 after the implantation of theVCMsustained-release
sheet. We then determined the ratio of PLCA and VCM in
order for the sheet to degrade in about 2 weeks.
MRSA was used as the test bacterium because if a
prosthetic graft infection with MRSA has developed in
critically ill patients, it is difficult to cure with conventional
treatments and sometimes leads to life-threatening condi-
n day 7 after the operation for animal experiment 3. A,
hematoxylin and eosin [HE] stain, 100). B, Severe
rmeation of inflammatory cells around the Dacron sheet
hiscence; yellow arrow, bacterial cells of as methicillin-
Only slight inflammation was seen as well as 3A (arrow,
l cells of MRSA (arrow) were found in the Dacron fiber
in theDacron fiber.GroupA, aDacron sheet andMRSA
oly-L-lactide-co-caprolactone (VCM-PLCA) sheet and
A sheet (without MRSA) (Gram stain, 400).eet o
eet) (
nd pe
in de
0). C,
cteria
ound
in -ptions such as sepsis.4,14 We selected the SR3737 strain from
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for two reasons. First, the SR3737 strain has the strongest
pathogenic activity among the MRSA strains available to
us. Second, although the MIC of VCM against most of
MRSA strains is generally no more than 2.0 g/mL, the
MIC against the SR3737 strain measured by our microbi-
ology laboratory was 2.0 g/mL.
The animal model created in the present study was
based on the knowledge that subcutaneously inoculated
MRSA would accumulate in the Dacron graft which is a
foreign material.15,16 Because bacterial cultures were neg-
ative in some samples, the standard deviation was relatively
large for the MRSA count in group D, and the number
decreased to 0.1% of that in the other groups.
The current study has some limitations. First, we simply
implanted the Dacron graft subcutaneously in our animal
model; thus, the environments for the prosthetic graft
infection in our model may be slightly different from that
encountered in clinical cases. Second, we used mice as our
experimental model, which may be more resistant against
infection than human patients. Further investigation is
therefore needed, including the replacement of the infected
graft in the arterial system with a larger animal model with
anatomic, physiologic, and immunologic features more
similar to those of humans.
CONCLUSION
One approach to the treatment of prosthetic graft
infection is in situ reconstruction, but its main drawback is
the risk of reinfection of the new graft at the infected area.17
The sustained-release sheet with VCMmay also represent a
useful adjuvant for the prevention of prosthetic graft rein-
fection in an in situ reconstruction. In addition, this strat-
egy may be used for the prevention of various kinds of local
MRSA reinfection, such as catheter-related infection, sur-
gical-site infection, and permanent pacemaker insertion site
infection.
Finally, prophylactic use of the sustained-release sheet
with VCM may be beneficial for critically ill patients who
often suffer from many complications, because the method
is topical with negligible systemic effects.
We conclude that the topical use of the sustained-
release sheet with VCM may represent a useful adjuvant to
prevent prosthetic graft infection due to MRSA.
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